Ifosfamide
Ifosfamide 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Non-Hodgkin Lymphoma、Burkitt Lymphoma、Diffuse Large B-Cell Lymphoma、Primary Mediastinal B-cell Lymphoma。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
24 项
全球在招研究
4 项
已进入 III/IV 期
26 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- New York Medical College
- University Hospital, Angers
- M.D. Anderson Cancer Center
- N.N. Petrov National Medical Research Center of Oncology
- Hoffmann-La Roche
- University of Birmingham
- Mayo Clinic
- Children's Oncology Group
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
法国、美国、Russia、澳大利亚、Brazil、中国、Czechia、丹麦、德国、Hungary、意大利、Poland
正在招募患者的 Ifosfamide 研究
Brain Irradiation for Childhood Cancer - Endocrine Monitoring During the First Years
不适用招募中法国NCT06618703Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma
不适用招募中美国NCT04199026High-dose Chemotherapy as Second-line Drug Therapy for Relapsed Germ Cell Tumors
II 期招募中RussiaNCT06418789A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma
I 期 / II 期招募中美国澳大利亚Brazil中国NCT05533775FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma
I 期 / II 期招募中澳大利亚奥地利比利时CzechiaNCT04625907Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
II 期招募中美国NCT03418038A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT
II 期招募中美国澳大利亚加拿大新西兰NCT04322318Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma
III 期招募中中国NCT06520163Efficacy and Safety of Envafolimab Plus Doxorubicin and Ifosfamide for Advanced Soft Tissue Sarcoma
II 期招募中中国NCT07243626Narlumosbartmab Combined With Neoadjuvant Chemotherapy in Bone-derived Malignancies With Osteolytic Lesions and Multinucleated Giant Cells
不适用招募中中国NCT06302465Chemo-immunotherapy in Patients Under 18 Years of Age With Bone and Soft Tissue Sarcomas
III 期招募中RussiaNCT06669013Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCL
II 期招募中中国NCT06489808Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes
I 期招募中美国NCT07194044Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer
I 期招募中美国NCT04701645Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017
III 期招募中澳大利亚奥地利Czechia德国NCT03643276International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma
III 期招募中奥地利比利时中国CzechiaNCT04043494Cabozantinib With Ifosfamide in Relapsed/Refractory Sarcomas
I 期招募中美国NCT06156410CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)
I 期招募中美国NCT04318678A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT
II 期招募中美国澳大利亚加拿大新西兰NCT04684368Observation Study to Evaluate the Efficacy and Safety of Ifosfamide/Mesna in Patients With Metastatic Castration-resistant Prostate Cancer
不适用招募中South KoreaNCT06236789Evaluation of Treatment Efficacy According to Risk Group in Relapsed Childhood Acute Lymphoblastic Leukemia
II 期招募中South KoreaNCT05827549Study of CD19 Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia
I 期招募中美国NCT04881240Paclitaxel/Ifosfamide/Cisplatin Chemotherapy for High Risk Pediatric Germ Cell Tumor
II 期招募中South KoreaNCT05455918Novel Targeted Drugs Combined With R-ICE Regimen in Relapsed and Refractory Diffuse Large B-cell Lymphoma
II 期招募中中国NCT05348213
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。